Here’s what you should know:
1. Immuron announced they secured the site initiation for the first-in-human, randomized, double-blind, placebo-controlled trial of IMM-529 Monday.
2. Immuron is hoping to enroll 60 patients by September 2017.
3. Patients will receive IMM-529 or a placebo three times a day for 28 days. Researchers will monitor both subsets for two months searching for recurrence of disease.
4. Researchers are assessing the safety and tolerability of IMM-529. The secondary endpoint is measuring for efficacy.
5. Immuron expects top-line results by the fourth quarter of fiscal year 2018.
More articles on quality:
Average OR time in ASCs versus hospitals: 5 key facts
New HHS pain management task force seeks nominations — 4 key notes
OptumRx reduced opioid dosage by 14%: Here’s how
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
